Myovant Sciences (NYSE: MYOV) and Ocera Therapeutics (NASDAQ:OCRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.

Profitability

This table compares Myovant Sciences and Ocera Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Myovant Sciences N/A -53.75% -48.90%
Ocera Therapeutics N/A -383.51% -134.92%

Institutional and Insider Ownership

79.2% of Myovant Sciences shares are held by institutional investors. Comparatively, 17.7% of Ocera Therapeutics shares are held by institutional investors. 2.8% of Myovant Sciences shares are held by insiders. Comparatively, 7.2% of Ocera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Myovant Sciences and Ocera Therapeutics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Myovant Sciences 0 0 4 0 3.00
Ocera Therapeutics 0 3 2 0 2.40

Myovant Sciences presently has a consensus target price of $22.50, indicating a potential upside of 80.58%. Ocera Therapeutics has a consensus target price of $4.19, indicating a potential upside of 133.94%. Given Ocera Therapeutics’ higher probable upside, analysts plainly believe Ocera Therapeutics is more favorable than Myovant Sciences.

Earnings and Valuation

This table compares Myovant Sciences and Ocera Therapeutics’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Myovant Sciences N/A N/A -$83.44 million ($1.41) -8.84
Ocera Therapeutics $610,000.00 77.79 -$26.89 million ($0.97) -1.85

Ocera Therapeutics has higher revenue and earnings than Myovant Sciences. Myovant Sciences is trading at a lower price-to-earnings ratio than Ocera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Ocera Therapeutics beats Myovant Sciences on 6 of the 11 factors compared between the two stocks.

About Myovant Sciences

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone, or LH, and follicle-stimulating hormone, or FSH, thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and prostate cancer. It intends to develop its second product candidate, RVT-602, for the treatment of female infertility as part of assisted reproduction.

About Ocera Therapeutics

Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.